To our knowledge, our data is the first study to evaluate the impact of LEF1 expression within the two Gal.3 level groups separately and demonstrated that LEF1high and low Gal.3 level patients were associated with favorable risk, better outcome in AML compared to others. The gene discussed is LEF1; the disease is acute myeloid leukemia.